---
title: "YD Bio highlights peer-reviewed computational study nominating keratoconus regenerative therapy targets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294821328.md"
description: "YD Bio highlighted a peer-reviewed computational study in Bioengineering that identifies potential regenerative therapy targets for keratoconus. The study ranks molecular candidates to guide future lab validation and exosome-based research. No clinical trials, market launches, or clinical outcomes were announced."
datetime: "2026-08-04T12:07:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294821328.md)
  - [en](https://longbridge.com/en/news/294821328.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294821328.md)
generator: "portal-rs"
---

# YD Bio highlights peer-reviewed computational study nominating keratoconus regenerative therapy targets

-   YD Bio highlighted a new peer-reviewed computational study on keratoconus in Bioengineering; no clinical trial or market launch was announced. \* Results have already been presented via publication; the work aims to guide future lab validation for regenerative approaches. \* The framework ranked molecular candidates that could inform exosome-based research; it did not test a therapy or report clinical outcomes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040800PRIMZONEFULLFEED9803122) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [YDES.US](https://longbridge.com/en/quote/YDES.US.md)
- [YDESW.US](https://longbridge.com/en/quote/YDESW.US.md)

## Related News & Research

- [YD Bio CEO Ethan Shen acquires 18,378 shares valued at $67,246.26](https://longbridge.com/en/news/298359096.md)
- [YD Bio Files First-Half 2026 Results, Reports Improved Equity Position](https://longbridge.com/en/news/297639743.md)
- [08:45 ETMicah Parsons Joins RejuvStem as Investor and Brand Ambassador](https://longbridge.com/en/news/298321840.md)
- [Vytrus Biotech says European skin rejuvenation patent validated in seven countries](https://longbridge.com/en/news/298226256.md)
- [YD Bio management commentary cites larger drug, medical product orders driving H1 2026 revenue up to $0.8 million](https://longbridge.com/en/news/297633109.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**